Comparative efficacy of intravesical perfusion therapy in non-muscle invasive bladder cancer : A systematic review and network meta-analysis-Reference-Cited by-同舟云学术

Comparative efficacy of intravesical perfusion therapy in non-muscle invasive bladder cancer : A systematic review and network meta-analysis

Published:2022-08-24 Issue: Volume: Page:
ISSN:
Container-title:
language:
Short-container-title:

Author:

Li Yangdong¹,Fan Maochuan¹,Zhang Shaohua¹,Meng Xiangzhen¹,Zhou Hao¹,Dou Qifeng¹

Affiliation:

1. the first clinical college of Xinxiang Medical University

Abstract

Abstract Background: Non-muscle invasive bladder cancer (NMIBC) has a high recurrence and progression rate, and its clinical treatment is diverse, but patient prognosis is not ideal. This meta-analysis was performed to assess the safety of different treatment regimens for NMIBC and provide a basis for clinical treatment. Methods: Randomized controlled trials (RCTs) on different drug regimens for NMIBC were searched by computer system in PubMed, SpringerLink, The Cochrane Library, OVID, CNKI, Wangfang, VIP. A total of 6 drugs were included. The language of the articles was limited to Chinese and English only, and the search time frame was from 2000-01-01 to 2022-05-01. Network meta-analysis of tumor recurrence rate, bladder irritation symptoms, and hematuria after different interventions for NMIBC using Stata15.1 software. Results: A total of six interventions were involved in the study:Bacillus Calmette-Gue´rin(BCG),epirubicin(EPI), gemcitabine (GEM), piricitabine (THP), mitomycin C(MMC), and hydroxycamptothecin(HCPT).The results showed that treatment with BCG was lower than treatment with EPI and MMC in terms of 1-year relapse rate; the area under the cumulative ranked probability plot (SUCRA) was ranked from lowest to highest: BCG<THP<GEM<EPI<MMC< HCPT. In terms of 2-year relapse rate, treatment with BCG was lower than treatment with GEM, EPI, THP, HCPT and MMC. The incidence of bladder irritation was significantly lower with GEM than with EPI and MMC, and significantly higher with BCG than with GEM, EPI, THP, and HCPT. SUCRA was ranked from lowest to highest: GEM<HCPT< THP < EPI < MMC< BCG. in terms of the incidence of hematuria, there was no statistical significance for each treatment measure. Conclusion: BCG treatment significantly reduced the recurrence rate of postoperative NMIBC, but did not reduce the incidence of bladder irritation and hematuria; GEM treatment was second only to BCG in reducing the recurrence rate, but it was effective in preventing the incidence of bladder irritation and hematuria.

Publisher

Research Square Platform LLC

Reference51 articles.

1. 1. Sylvester R J, van der Meijden A P, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials[J]. Eur Urol, 2006,49(3):465–466, 475–477.

2. 2. O'Brien T, Ray E, Singh R, et al. Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicentre, randomised clinical trial of a single postoperative intravesical dose of mitomycin C (the ODMIT-C Trial)[J]. Eur Urol, 2011,60(4):703–710.

3. 3. Babjuk M, Böhle A, Burger M, et al. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016[J]. Eur Urol, 2017,71(3):447–461.

4. 4. Rades D, Manig L, Janssen S, et al. Concurrent Chemotherapy Improves the Overall Survival of Patients Irradiated for Locally Recurrent Bladder Cancer[J]. Anticancer Res, 2017,37(3):1485–1488.

5. 5. Hutton B, Salanti G, Caldwell D M, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations[J]. Ann Intern Med, 2015,162(11):777–784.